ArticleJournal of clinical laboratory analysis2026
Compare Serum VCAM-1, NSE, Procalcitonin in Predict Sepsis Induced Encephalopathy in Septic Patients.
Article in Journal of clinical laboratory analysis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSepsis-associated encephalopathy (SAE) is a common complication of severe sepsis. Increased concentration of Vascular Cell Adhesion Molecule 1 (VCAM-1) is associated with SAE in a previous study. Neuron-specific enolase (NSE) was shown to be related to brain injury in cardiac arrest and trauma patients and procalcitonin was associated with the severity of sepsis. But their relationship with sepsis-associated encephalopathy was unknown.
objectiveThis study aimed to compare VCAM-1 with NSE and procalcitonin in association with sepsis-associated encephalopathy.
methodsFifty-nine adult patients with sepsis admitted through the emergency department were evaluated. VCAM-1, NSE, and procalcitonin were assessed for their relationship with SE and compared with other clinical predictors and biomarkers.
results29 (49%) patients had SAE. SAE group had higher VCAM-1 (1891.9 [1513.3-3229.9] vs. 1562.3 [1034.9-1892.9]), and lactate levels (32.1 [17.5-53.9] vs. 15 [10.3-24]) on admission than the non-SAE group. NSE and procalcitonin were not statistically significantly associated with sepsis-associated encephalopathy. Serum VCAM-1 is associated with procalcitonin (ρ = 0.433, p < 0.01) but not NSE (ρ = -0.208, p = 0.114). Serum VCAM-1 level can be used to predict sepsis-associated encephalopathy on Day 1, Day 4, Day 7 of sepsis. The AUC analysis of the ROC curve of serum sVCAM-1 showed that Day 7 had a higher AUC 0.856 (0.746-0.966) than Day 4 (0.802 [0.674-0.929]) and Day 1 (0.711 [0.563-0.859]).
conclusionSerum VCAM-1 serves as a significant predictor of sepsis-associated encephalopathy as defined in this study within the first seven days of sepsis identification. In contrast, NSE and procalcitonin did not demonstrate statistically significant associations with sepsis-induced encephalopathy in this study.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.